Jae Il Chung

Title: Jae Il Chung: Innovator in Prostate Cancer Biomarkers

Introduction

Jae Il Chung is a prominent inventor based in Busan, South Korea. He has made significant contributions to the field of cancer diagnostics, particularly in the area of prostate cancer. His innovative work focuses on the development of biomarker compositions that aid in the diagnosis and prognosis of metastatic prostate cancer.

Latest Patents

Jae Il Chung holds a patent for a "Circulating tumor cell based biomarker composition for diagnosis and prognosis of metastatic prostate cancer." This invention relates to a biomarker composition that enhances the detection rate and expression level of a gene combination composed of AR (Androgen receptor), AR-V7 (Androgen receptor variant 7), EpCAM (Epithelial cell adhesion molecule), KRT-19 (Cytokeratin 19), PSA (Prostate specific antigen), and PSMA (Prostate specific membrane antigen) in circulating tumor cells (CTCs) isolated from patients. The gene combination serves as a reliable biomarker for both the diagnosis and prognosis prediction of prostate cancer.

Career Highlights

Throughout his career, Jae Il Chung has worked with esteemed institutions, contributing to advancements in medical research and technology. His work has been instrumental in enhancing the understanding of prostate cancer biomarkers and their implications for patient care.

Collaborations

Jae Il Chung has collaborated with notable colleagues, including Jae Seung Chung and Ki-Ho Han. These partnerships have fostered innovation and have been pivotal in the development of his patented technologies.

Conclusion

Jae Il Chung's contributions to the field of prostate cancer diagnostics exemplify the impact of innovative research on healthcare. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes in cancer treatment.